Simulations Plus SLP QSP/QST Services — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Simulations Plus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Simulations Plus’s 10-K, filed December 1, 2025, on SEC EDGAR. View the filing →
Ask your AI about Simulations Plus's qsp/qst services — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Simulations Plus's QSP/QST services — revenue?
- Simulations Plus (SLP) reported QSP/QST services — revenue of $1.63M in Q2 2025.
- How has Simulations Plus's QSP/QST services — revenue changed year-over-year?
- Simulations Plus's QSP/QST services — revenue decreased by 26.5% year-over-year, from $2.22M to $1.63M.
- What is the long-term trend for Simulations Plus's QSP/QST services — revenue?
- Over 2 years (2023 to 2025), Simulations Plus's QSP/QST services — revenue has grown at a 7.3% compound annual growth rate (CAGR), from $5.68M to $6.54M.
- What does QSP/QST services — revenue mean?
- This metric represents the total revenue generated from Quantitative Systems Pharmacology (QSP) and Quantitative Systems Toxicology (QST) consulting and contract research services. It reflects the company's ability to monetize specialized scientific expertise and modeling services provided to pharmaceutical and biotechnology clients. Monitoring this revenue stream helps assess the demand for high-end, project-based research support within the broader drug development lifecycle.